Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
Rhea-AI Summary
Heron Therapeutics (Nasdaq: HRTX) will report first quarter 2026 financial results on Monday, May 11, 2026 at 8:30 a.m. ET via a conference call and live webcast.
The call requires registration for dial-in details; participants are encouraged to dial in 15 minutes early. A webcast and a 60-day archive will be available on Heron's Investor Relations website at www.herontx.com.
Positive
- None.
Negative
- None.
News Market Reaction – HRTX
In the Apr 28 session, HRTX gained 1.68%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.2% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Earnings date notice | Neutral | +3.5% | Announced date and time for Q4 and full-year 2025 results call and webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news saw a modest positive move, indicating investors have previously reacted constructively to similar announcements.
Over the last several months, Heron’s key milestones included strong 2025 revenue growth, updated 2026 guidance, and positive Acute Care franchise momentum, as seen in earnings on Feb 26, 2026 and prior updates. The last earnings-date notice on Feb 17, 2026 preceded a 3.48% gain. Today’s announcement sets expectations for Q1 2026 results and continues that cadence of scheduled financial disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, May 11, 2026, at 8:30 a.m. ET to report first quarter 2026 financial results and discuss recent business highlights.
The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron’s website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
